ACD-101 is under clinical development by Therapeia and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Glioblastoma Multiforme (GBM) have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ACD-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ACD-101 overview
ACD-101 (131I-ACD-101) is under development for the treatment of glioblastoma multiforme, recurrent glioblastoma multiforme. The drug is administered intravenously. ACD-101 is a phenylalanine derivative that contains an iodine atom. It is a synthetic amino acid. ACD-101 is a radiation sensitizer which increases tumor killing in connection with standard external field radiation therapy (XRT), or intracellular endo-radiation therapy (ERT), using 131I-ACD-101. It acts by targeting DNA and LAT-1 (L-type amino acid transporter).
See Also:
Therapeia overview
Therapeia is a developer of diagnostic and therapeutic radiopharmaceuticals for unmet medical needs. The company’s products include ACD-101 which include 131I-ACD-101 and 124I-ACD-101. It offers ACD-101 which is administered intravenously over the intact blood brain barrier into tumour tissue and has an anti cancer effect. Therapeia is radio actively labeled with 131I and is used for therapy (131I-ACD-101). The company provides ACD-101 which is also used as a PET tracer for diagnosis (124I-ACD-101), when radio labelled with 124I. Its products find it’s application in the therapeutic areas of glioma or brain cancer. It also offers cancer treatments such as cytotoxic chemotherapeutics. Therapeia is headquartered in Dresden, Germany.
For a complete picture of ACD-101’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
